Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio

FDA 510(k) K242706 · Fujirebio Diagnostics,Inc.

Substantially Equivalent

510(k) numberK242706

Submission

Device name
Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio
Applicant
Fujirebio Diagnostics,Inc.
Malvern, PA, US
Received
September 9, 2024
Decision date
May 16, 2025
Decision
Substantially Equivalent (SESE)
Type
Traditional 510(k)
Summary
510(k) summary available from FDA

Official FDA 510(k) record

Device classification

Product code
SET – Immunoassay Blood Test For Amyloid Pathology Assessment
Device class
Class II (moderate risk)
Regulation
21 CFR 866.5840
Specialty
Immunology

An Immunoassay blood test for amyloid pathology assessment is an in vitro diagnostic test used to identify patients with amyloid pathology associated with Alzheimer’s Disease who have signs and symptoms of cognitive decline. The results of the test are to be interpreted in conjunction with other patient clinical information.

Other 510(k)s with product code SET

510(k)DeviceApplicantDecision
K261686Elecsys Phospho-Tau (217P) PlasmaSET · Traditional Roche Diagnostics08/19/2026SE
K253240PrecivityAD2 TestSET · Traditional C2N Diagnostics, LLC08/19/2026SE
K252163Elecsys Phospho-Tau (181P) PlasmaSET · Traditional Roche Diagnostics10/08/2025SE

More from Roche Diagnostics

510(k)DeviceDecision
K250925ADVIA Centaur Cytokeratin Fragment 21-1OVK · Traditional 12/16/2025SE
K192524Lumipulse G CA15-3MOI · Traditional 09/04/2020SE
K192380ST Aia-Pack BNPNBC · Traditional 08/24/2020SE
K200997Lumipulse G CA19-9-NNIG · Special 05/14/2020SE
K190702Lumipulse G whole PTHCEW · Traditional 08/30/2019SE
K172713Lumipulse G B•R•A•H•M•S PCT Immunoreaction Cartridges, Lumipulse G B•R•A•H•M•S PCT…PRI · Traditional 12/10/2017SE
K171103Lumipulse G TSH-III Immunoreaction CartridgesJLW · Traditional 07/28/2017SE
K163546Lumipulse G Progesterone-N CalibratorsJIT · Abbreviated 01/13/2017SE
K163534Lumipulse G FSH-N CalibratorsJIT · Abbreviated 01/13/2017SE
K163544Lumipulse G ProlactinJIT · Abbreviated 01/12/2017SE

Questions and answers

When was Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio cleared by the FDA?

Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio (K242706) received a 510(k) decision of Substantially Equivalent on May 16, 2025, 249 days after the submission was received.

What is the product code of K242706?

The FDA product code is SET – Immunoassay Blood Test For Amyloid Pathology Assessment, a Class II (moderate risk) device regulated under 21 CFR 866.5840.